Acoramidis ATTR Cm denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for acoramidis attr cm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Step Therapy for Acoramidis in ATTR-CM — and How to Appeal

A step-therapy denial for acoramidis in transthyretin amyloid cardiomyopathy means Aetna's policy requires documentation that the patient has tried and failed — or has a clinical reason to bypass — one or more prior therapies before acoramidis will be covered. In the ATTR-CM therapeutic landscape, where multiple TTR-targeting agents now exist with different mechanisms (stabilizers vs. silencers), step-therapy protocols are increasingly applied.

This type of denial is frequently winnable, because: (1) many patients with ATTR-CM have tried earlier-available therapies; (2) some patients have clinical characteristics that make certain prior-step agents unsuitable; and (3) the agents in this space are not freely interchangeable — mechanism, route, and patient-specific factors matter.

## Why This Denial Is Appealable

Under ACA §2719 and ERISA §503, step-therapy protocols must account for the individual patient's clinical circumstances. You have the right to a full-and-fair internal review, and if that fails, an independent external review within approximately four months of the final internal denial. Many states also have step-therapy override laws requiring insurers to grant exceptions when: the required prior step is clinically inappropriate for the patient, the patient has already failed the required step, or step therapy would cause harm or serious disease progression. Confirm whether your state's law applies.

## Your Appeal Timeline

• Internal appeal: File within 180 days of the denial notice (verify on your Explanation of Benefits).
• External review: Within approximately four months of the final internal denial.
• Expedited track: Available when the patient's condition is urgent; ATTR-CM is progressive and deterioration during delay may support an expedited request.

## Documentation to Gather

1. Prior-treatment history with dates and outcomes: For each agent Aetna's policy lists as a required prior step, document whether the patient tried it (dates, duration, outcome) or why it was not appropriate (contraindication, clinical unsuitability, or unavailability at the time of initial treatment). 2. Mechanism and clinical distinction from required prior-step agents: Ask the treating cardiologist to explain in writing why the required prior-step agent(s) are not clinically interchangeable with acoramidis for this patient. 3. Current disease stage and urgency: Chart documentation of the patient's current functional status, any recent deterioration, and why delay for a step-therapy trial would be harmful. 4. Prescriber medical-necessity letter: A letter from the treating cardiologist addressing each step-therapy requirement directly — either showing the step was completed or explaining why an exception is warranted. 5. Applicable guideline reference: Note whether the relevant cardiology society guideline organization (e.g., ACC/AHA) supports direct use of acoramidis for this patient's subtype and disease stage without requiring the denied prior steps.

## Criteria-Mapping Structure

Obtain Aetna's step-therapy criteria for acoramidis from the relevant Clinical Policy Bulletin.

| Step-Therapy Requirement | Chart Evidence or Exception Basis | |---|---| | Prior-step agent #1 tried | [Agent, dates, outcome — or reason not appropriate] | | Prior-step agent #2 tried | [Agent, dates, outcome — or reason not appropriate] | | Adequate trial duration documented | [Duration per chart] | | Clinical failure or intolerance | [Chart note, prescriber statement] | | Exception basis (if prior step not tried) | [Clinical unsuitability rationale, guideline support] |

A step-therapy appeal that either walks through completed prior steps or articulates a documented clinical reason for each exception — with chart evidence, not just assertions — is the most effective format.